Modalis Therapeutics Corporation

Equities

4883

JP3922600006

Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 02:00:00 2024-05-16 am EDT			5-day change	1st Jan Change
66 ^JPY	-5.71%		-9.33%	-45.16%

May. 07	Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101	CI
Apr. 30	Modalis Therapeutics Corporation to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy at the Global Cell & Gene Therapy Summit	CI

Modalis Therapeutics Corporation Announces Consolidated Earnings Results for the Six Months Ended June 30, 2021

August 05, 2021 at 02:00 am EDT

Modalis Therapeutics Corporation announced consolidated earnings results for the six months ended June 30, 2021. For the period, the company reported operating revenue of JPY 1 million compared to JPY 337 million a year ago. Operating loss was JPY 477 million compared to JPY income of JPY 29 million a year ago. Profit attributable to owners of parent was JPY 17 million compared to JPY 26 million a year ago. Basic EPS was JPY 0.62 compared to JPY 1.07 a year ago.

Latest news about Modalis Therapeutics Corporation

Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101	May. 07	CI
Modalis Therapeutics Corporation to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy at the Global Cell & Gene Therapy Summit	Apr. 30	CI
Modalis Therapeutics to See Reduced Expenses of 250 to 350 Million After Cutting Jobs	Apr. 14	MT
Modalis Therapeutics to Reduce Stated Capital and Capital Reserves	Feb. 23	MT
Japanese Shares Continue to Track Wall Street Higher as Investor Caution Ahead of US Rate Decision Caps Gains	Dec. 13	MT
Modalis Therapeutics, JCR Pharmaceuticals Form Drug Delivery Research Partnership	Dec. 12	MT
Modalis Therapeutics Corporation and JCR Pharmaceuticals Enter into Joint Research Agreement	Dec. 12	CI
Modalis Therapeutics Corporation announced that it has received ¥505.320864 million in funding from Evolution Capital Management LLC	Nov. 29	CI
Modalis Therapeutics Corporation announced that it expects to receive ¥505.320864 million in funding from Evolution Capital Management LLC	Nov. 06	CI
Modalis Therapeutics Corporation cancelled the transaction announced on September 11, 2023	23-09-27	CI
Modalis Therapeutics Corporation announced that it expects to receive ¥18.77952 million in funding from China Silver Asset Management Hong Kong Limited	23-09-10	CI
Modalis Therapeutics Corporation to Regain Full Rights to MDL-201 and MDL-202 from Astellas Pharma Inc	23-08-07	CI
Modalis Therapeutics Corporation Receives Positive FDA Response for Pre-IND Review for MDL-101 Clinical Development	23-06-25	CI
Modalis Therapeutics to Grant Stock Options	23-06-16	MT
Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Modalis Therapeutics Corporation to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of A Type of Muscular Dystrophy At the ASGCT Annual Meeting	23-04-19	CI
Modalis to Allot Stock Options	23-03-29	MT
Modalis Therapeutics to Overcome 2.6 Billion Yen Deficit in Retained Earnings	23-02-23	MT
Modalis Therapeutics Corporation Announces Notice of Termination of A Research Collaboration on 205	23-01-12	CI
Modalis Therapeutics Corporation(TSE:4883) dropped from S&P Global BMI Index	22-09-19	CI
Modalis Therapeutics Issues Share Acquisition Rights	22-07-06	MT
Modalis Therapeutics to Issue Share Acquisition Rights	22-06-16	MT
Modalis Therapeutics Swings to Loss in Q1 on Growing Research Costs	22-05-10	MT
Modalis Therapeutics Adds Cardiomyopathy Therapy to In-House Pipeline	22-05-10	MT
Modalis Therapeutics Corporation Announces Addition of MDL-105 to In-house Pipelines	22-05-09	CI

Chart Modalis Therapeutics Corporation

Duration

Period

More charts

Company Profile

Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.

Sector

Biotechnology & Medical Research

Calendar

2024-08-01 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
MODALIS THERAPEUTICS CORPORATION	-45.16%	15.46M
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	113B
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B
BIONTECH SE	-12.64%	22.22B
ARGENX SE	+0.44%	22.27B
GENMAB A/S	-4.18%	19.43B
WUXI APPTEC CO., LTD.	-37.85%	17.87B
BEIGENE, LTD.	-8.58%	17.24B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.52B
LEGEND BIOTECH CORPORATION	-23.95%	8.34B

Bio Therapeutic Drugs